NCT01551706已完成1 期
A Randomized, Double-blind, Placebo-controlled, Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Change from baseline on oxidation stress biomarkers including total antioxidant capacity, superoxide dismutase (SOD), 8-OHdG and 8-isoprostane
研究概览
简要总结
This is a Randomized, Double-blind, Placebo-controlled, Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status.
详细描述
This study will investigate the effect of ENI Patented Whole Grape Extract versus placebo on antioxidant status. The primary objective is to determine antioxidant status by measuring total antioxidant capacity and superoxide dismutase (SOD) in blood and 8-OHdG and 8-isoprostane in first morning void urine samples prior to and after six weeks of supplementation with ENI Patented Whole Grape Extract.
Secondary objectives will include the assessment of oxidized LDL (oxLDL) and safety evaluations:
- oxLDL
- Safety laboratory tests: CBC, electrolytes, glucose, creatinine, eGFR, AST, ALT, GGT,bilirubin
- Vital signs: heart rate and blood pressure
- Adverse events
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 18 - 65 years of age
- •If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).
- •OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
- •Double-barrier method (condoms with spermicide or diaphragm with spermicide)
- •Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- •Intrauterine devices
- •Vasectomy of partner (shown successful as per appropriate follow-up)
- •Abstinence
- •One or more of the following conditions:
- •Pre-hypertension defined as diastolic blood pressure of 80-89 mmHg and systolic blood pressure of 139 or lower at screening
- •BMI from 25.0 to 34.9 kg/m2
- •Pre-diabetes defined as a fasting plasma glucose from 5.2 to 6.9 mmol/L
- •Subjects who are smokers agree to report smoking habits at each visit and do not plan on changing their smoking habits during the study.
- •Has given voluntary, written, informed consent to participate in the study
排除标准
- •Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
- •Subject has any clinically significant medical conditions including cardiovascular disease,hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90mmHg), diabetes, liver or kidney disease
- •Use of medication for the treatment of hypertension
- •Use of medication for vasodilation, including nitric oxide releasing patches
- •Use of medication for erectile dysfunction
- •Use of medication (prescribed or over the counter) for weight loss
- •Use of statins, fibrates, niacin, or any other medication for the treatment of hypercholesterolemia
- •Use of anticoagulants
- •Use of illicit drugs or history of drug or alcohol abuse with the past 5 years (currently having more than 2 standard alcoholic drinks per day)
- •Use of natural health products (NHPs)/dietary supplements that are known to have significant antioxidant activity within 2 weeks prior to baseline and during the course of the study including but not limited to vitamins A, C, and E, selenium and zinc.
- •Participation in a clinical research trial within 30 days prior to baseline
- •Clinically significant abnormal laboratory results at screening including
- •AST, ALT and/or bilirubin > 2 x the ULN
- •Serum creatinine >1.5 x the ULN or eGFR < 60
- •hemoglobin < 140 g/L for males and < 123 g/L for females
- •Allergy or sensitivity to test product ingredients
- •Individuals who are cognitively impaired and/or who are unable to give informed consent
- •Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
结局指标
主要结局
Change from baseline on oxidation stress biomarkers including total antioxidant capacity, superoxide dismutase (SOD), 8-OHdG and 8-isoprostane
时间窗: 6 weeks
This study will investigate the effect of ENI Patented Whole Grape Extract versus placebo on antioxidant status. The primary objective is to determine antioxidant status by measuring total antioxidant capacity and superoxide dismutase (SOD) in blood and 8-OHdG and 8-isoprostane in first morning void urine samples prior to and after six weeks of supplementation with ENI Patented Whole Grape Extract.
次要结局
- Change from baseline in oxidized LDL (oxLDL).(6 weeks)
- Change from baseline in safety lab test biomarkers including CBC, electrolytes, glucose, creatinine, eGFR, AST, ALT, GGT, and bilirubin(6 weeks)
- Change from baseline in vital signs: heart rate and blood pressure(6 weeks)
- Number of participants with adverse events(6 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for InhalationCOVID-19NCT04840992CanSino Biologics Inc.840
已完成
2 期
A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With RosaceaRosaceaNCT01614743DeNova Research9
Unknown
1 期
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Esophageal CancerNCT04460066Lee's Pharmaceutical Limited70
终止
4 期
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn VictimsPost-traumatic Stress DisorderNCT02520726University of Utah5
终止
2 期
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19COVID-19NCT04474483State University of New York at Buffalo8